Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 459, doi. 10.1002/cpdd.977
- Publication type:
- Article
Works matching IS 2160763X AND DT 2023 AND VI 12 AND IP 5
Results: 11
1
2
Safety, Tolerability, and Pharmacokinetics of IMU‐935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double‐Blind, Placebo‐Controlled, First‐in‐Human Phase 1 Study
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 525, doi. 10.1002/cpdd.1243
- By:
- Publication type:
- Article
3
Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 475, doi. 10.1002/cpdd.1240
- By:
- Publication type:
- Article
4
The Oral Bioavailability and Effect of Various Gastric Conditions on the Pharmacokinetics of Dersimelagon in Healthy Adult Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 493, doi. 10.1002/cpdd.1235
- By:
- Publication type:
- Article
5
Comparative Bioavailability of a Novel Solution and a Tablet Formulation of Levothyroxine.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 502, doi. 10.1002/cpdd.1233
- By:
- Publication type:
- Article
6
Exposure–response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 463, doi. 10.1002/cpdd.1232
- By:
- Publication type:
- Article
7
Effect of Multiple Doses of Sparsentan on the Single‐Dose Pharmacokinetics of Dapagliflozin: An Open‐Label Drug–Drug Interaction Study in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 535, doi. 10.1002/cpdd.1231
- By:
- Publication type:
- Article
8
Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and the Reference Drug in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 518, doi. 10.1002/cpdd.1221
- By:
- Publication type:
- Article
9
Evaluation of Pharmacokinetics and Safety With Bioequivalence of Voriconazole Injection of 2 Formulations in Chinese Healthy Volunteers: Bioequivalence Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 542, doi. 10.1002/cpdd.1218
- By:
- Publication type:
- Article
10
Relative Bioavailability and Food Effect of Asciminib Pediatric Mini‐tablet Formulation Compared to the Reference Tablet Formulation in Healthy Adult Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 484, doi. 10.1002/cpdd.1213
- By:
- Publication type:
- Article
11
Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 509, doi. 10.1002/cpdd.1219
- By:
- Publication type:
- Article